Increased healthcare utilization costs following initiation of insulin treatment in type 2 diabetes: A long-term follow-up in clinical practice

Increased healthcare utilization costs following initiation of insulin treatment in type 2 diabetes : A long-term follow-up in clinical practice

Funding Agencies|AstraZeneca
Aims: To compare long-term changes in healthcare utilization and costs for type 2 diabetes patients before and after insulin initiation, as well as healthcare costs after insulin versus non-insulin anti-diabetic (NIAD) initiation. Methods: Patients newly initiated on insulin (n = 2823) were identified in primary health care records from 84 Swedish primary care centers, between 1999 to 2009. First, healthcare costs per patient were evaluated for primary care, hospitalizations and secondary outpatient care, before and up to seven years after insulin initiation. Second, patients prescribed insulin in second line were matched to patients prescribed NIAD in second line, and the healthcare costs of the matched groups were compared. Results: The total mean annual healthcare cost increased from 1656 per patient 2 years before insulin initiation to 3814 seven years after insulin initiation. The total cumulative mean healthcare cost per patient at year 5 after second-line treatment was 13,823 in the insulin group compared to 9989 in the NIAD group. Conclusions: Initiation of insulin in type 2 diabetes patients was followed by increased healthcare costs. The increases in costs were larger than those seen in a matched patient population initiated on NIAD treatment in second-line. (C) 2016 The Author(s). Published by Elsevier Ltd on behalf of Primary Care Diabetes Europe. This is an open access article under the CC BY-NC-ND license.

Bodegard, JohanAstraZeneca Nord Balt, Sodertalje, Sweden. (author)
Sundström, JohanUppsala University,Uppsala universitet,Uppsala kliniska forskningscentrum (UCR),Uppsala University, Sweden(Swepub:uu)johasund (author)
Svennblad, BodilUppsala University,Uppsala universitet,Uppsala kliniska forskningscentrum (UCR),Ortopedi,Uppsala University, Sweden(Swepub:uu)bosve677 (author)
Östgren, Carl JohanLinköpings universitet,Linköping University,Avdelningen för samhällsmedicin,Medicinska fakulteten,Region Östergötland, Vårdcentralen Ödeshög(Swepub:liu)caros18 (author)
Nilsson-Ehle, PeterLund University,Lunds universitet,Avdelningen för klinisk kemi och farmakologi,Institutionen för laboratoriemedicin,Medicinska fakulteten,Division of Clinical Chemistry and Pharmacology,Department of Laboratory Medicine,Faculty of Medicine(Swepub:lu)kkem-pne (author)
Johansson, GunnarUppsala University,Uppsala universitet,Allmänmedicin och preventivmedicin,Uppsala University, Sweden(Swepub:uu)gunnarjs (author)
Ekman, ManiasAstraZeneca Nord Balt, Sodertalje, Sweden. (author)
Nilsson Nilsson, PeterLund University, Sweden (author)
AstraZeneca Nord Balt, Sodertalje, Sweden.Uppsala kliniska forskningscentrum (UCR) (creator_code:org_t)

By the author/editor: Kalkan, Almina; Bodegard, Johan; Sundström, Johan; Svennblad, Bodil; Östgren, Carl Jo ...; Nilsson-Ehle, Pe ...; show more...; Johansson, Gunna ...; Ekman, Manias; Nilsson Nilsson, ...; show less...

About the subject

MEDICAL AND HEALTH SCIENCES: MEDICAL AND HEAL ...; and Clinical Medicin ...; and Endocrinology an ...

MEDICAL AND HEALTH SCIENCES: MEDICAL AND HEAL ...; and Health Sciences; and Health Care Serv ...

By the university: Uppsala University; Lund University; Linköping University

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.